GlassScriptPhysician profile
Ayoub Innabi
NPI 1346636735
$1,056.19
in general payments reported to CMS, 2019-2025
16 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.62 · 2023: $116 · 2024: $361 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $287.26 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $124.74 | 2025 | Breztri |
| Regeneron Healthcare Solutions, INC. | $94.82 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.81 | 2023-2025 | Ofev, Jascayd |
| Genzyme Corporation | $86.58 | 2024-2025 | |
| Viatris Specialty LLC | $67.12 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $63.39 | 2024-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $46.18 | 2023-2024 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $40.04 | 2025 | |
| Insmed, INC. | $29.91 | 2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $25.81 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.18 | 2024 | Glassia |
| United Therapeutics Corporation | $23.94 | 2025 | Tyvaso |
| Mylan Specialty L.P. | $22.22 | 2023 | Yupelri |
| Verona Pharma, INC. | $16.90 | 2025 | Ohtuvayre |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $15.29 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayoub Innabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.